On August 21, 2026, leading US oncology panels updated clinical protocols for antibody-drug conjugates (ADCs) in HER2-low and HER2-positive breast cancers. Sourcing authentic options like Enhertu (Trastuzumab Deruxtecan) 100mg Injection is a critical priority for patients management.

At Onco Medicine, we specialize in verified cold-chain shipping of biological cancer therapies to the United States, supporting patients with original products and complete customs compliance.

ADC Target Mechanism in Breast Cancer

Trastuzumab deruxtecan is a HER2-directed antibody-drug conjugate that delivers a topoisomerase I inhibitor payload directly to cancer cells:

• Targeted Cytotoxic Delivery: The monoclonal antibody targets HER2 receptors, releasing the cytotoxic payload inside the cell to destroy it.
• Bystander Effect: The payload is membrane-permeable, allowing it to destroy neighboring cancer cells even if they have low HER2 expression.
• Cold Chain Sensitivity: Must be kept at 2-8°C during transit to prevent protein degradation.

FDA Personal Importation Policy Compliance

US patients can legally import specialized medications under the FDA Personal Importation rules:

• US Oncologist Prescription: A valid US prescription detailing the diagnosis is mandatory.
• 90-Day Supply Limit: Shipments are limited to a maximum 3-month supply.
• Cold-Chain Security: Shipped in validated containers with live data loggers to ensure a strict 2-8°C window.

Secure Professional Sourcing & Support

For inquiries regarding batch availability, legal clearance documentation, or pricing details, please reach out to our dedicated support desk at support@onco-medicine.com. You can also connect directly with a qualified pharmacist via our verified WhatsApp Support Line at +91 94275 19809.